Childhood Immune Thrombocytopenic Purpura: Diagnosis and Management
Section snippets
Pathophysiology
The pathophysiology of ITP increasingly is understood better (reviewed by Cines and Blanchette [1]). Not surprisingly, it is complex with involvement of many players in the human immune orchestra, including antibodies, cytokines, antigen-presenting cells, costimulatory molecules, and T and B lymphocytes (including T-helper, T-cytotoxic, and T-regulatory lymphocytes). Current knowledge is summarized later.
A key element in the pathophysiology of ITP is loss of self tolerance leading to the
Differential diagnosis
Primary ITP is a diagnosis of exclusion. The question, “When does a low platelet count not mean ITP?” is important, especially for atypical cases. When an unexpected low platelet count in a child is obtained, artifact or laboratory error should be considered first and excluded. Pseudothrombocytopenia is an example of spurious thrombocytopenia that is caused by platelet aggregation and clumping in the presence of ethylenediamine tetraacetic acid (EDTA) anticoagulant [9]. Examination of
Clinical and laboratory features
Thrombocytopenia for less than 6 months defines the entity acute ITP. Typically, children who have acute ITP are young, of previous good health, and present with sudden onset of bruising or a petechial rash. In a series of 2031 children who had newly diagnosed ITP, reported by Kühne and colleagues [12] in 2001 for the Intercontinental Childhood ITP Study Group (ICIS), the mean age at presentation was 5.7 years. Approximately 70% of the cohort were children ages 1 to 10 years with 10% of the
Observation
The case for observation of children who have acute ITP rests with the knowledge that acute ITP is, for the majority of affected children, a benign self-limiting disorder, usually with mild clinical symptoms and has a low risk for serious bleeding (approximately 3% with ICH being rare) and the fact that there are no prospective studies that clearly indicate a decrease in the incidence of ICH associated with treatment [32]. Several children who had ITP-associated ICH were receiving
To perform a bone marrow aspirate or not
There is consensus that bone marrow aspiration is not necessary for children who have newly diagnosed typical acute ITP if management involves observation or plasma based therapies, such as IVIG or anti-D. The contentious issue is whether or not a bone marrow aspirate should be performed in children who have typical acute ITP before starting corticosteroids to avoid missing, and therefore treating inappropriately, an underlying leukemia. The results of a retrospective study of bone marrow
To hospitalize or not
The majority of children who have newly diagnosed acute ITP and platelet counts less than 20 × 109/L are hospitalized. The figure was 83% in the first United Kingdom National Survey [14] and 78% of 1995 children who had newly diagnosed ITP reported by Kühne and colleagues [12] on behalf of the ICIS. This high hospitalization rate is driven by the decision to treat and the perceived need for a bone marrow aspirate before starting corticosteroid therapy. If a conservative management approach is
Chronic immune thrombocytopenic purpura
Conventionally, chronic ITP is defined as thrombocytopenia (platelet count less than 150 × 109/L) persisting for longer than 6 months from the onset of illness. Using this definition, approximately 20% to 25% of children manifest chronic ITP at 6 months after the initial diagnosis of ITP. Many children who have platelet counts in the range of 30 to 150 × 109/L, however, require no platelet-enhancing therapy and some enter a spontaneous complete remission in the 6 to 24 months after initial
Presplenectomy management
Medical management is preferred over splenectomy for children who have chronic ITP for less than 12 months. Treatment options include oral corticosteroids (including pulse oral dexamethasone), IVIG, and IV anti-D (reviewed by Blanchette and Price [56]). Avoidance of medications known to affect platelet function adversely, especially aspirin, should be stressed and high-risk competitive or contact activities should be avoided during periods of severe thrombocytopenia. The goal should be to
Protection against overwhelming postsplenectomy infection
Before elective splenectomy, children who have ITP should be immunized with the hemophilus influenza type b and pneumococcal vaccines; depending on their age and immunization history, meningococcal vaccine also is recommended [66]. Because the protection provided after immunization is incomplete (not all pneumococcal serotypes are included in the currently available vaccines), daily prophylaxis with penicillin, or an equivalent antibiotic if the child is allergic to penicillin, is recommended
Emergency treatment
On rare occasions, children who have acute ITP and severe thrombocytopenia may manifest symptoms or signs suggestive of organ- or life-threatening hemorrhage (eg, ICH). Management of such cases is challenging and should involve measures that have the potential to increase the circulating platelet count rapidly. An approach commonly used involves the immediate IV administration of methylprednisolone (30 mg/kg, maximum dose 1 g) over 20 to 30 minutes plus a larger than usual (two- to threefold)
Combined cytopenias
The combination of ITP and clinically significant autoimmune hemolytic anemia (Evans's syndrome) or autoimmune neutropenia occurs in a minority of cases [69], [70], [71], [72], [73]. Affected children often are older than those who present with typical acute ITP. The clinical course is variable and often prolonged with significant morbidity and mortality reported in retrospective series (Table 3). Response to single-agent therapy or splenectomy often is poor [74]; combination immunosuppressive
New therapies
First-line therapies in children include corticosteroids, high-dose IVIG, and, for children who are rhesus positive, IV anti-D. Splenectomy is the traditional second-line treatment of those children who have well-established, symptomatic chronic ITP who have failed or are intolerant of first-line therapies. An array of third-line therapies is available for children in whom splenectomy is refused or contraindicated. Agents include azathioprine, cyclophosphamide, danazol, vinca alkaloids,
Future directions
Although much has been learned about the pathogenesis and treatment of ITP over the past 3 decades, many questions remain unanswered. Optimal management of children who have newly diagnosed acute ITP and platelet counts less than 20 × 109/L remains the subject of debate and there is an urgent need for a well-designed large trial to address the issues of to treat or not, to perform a bone marrow aspirate or not, and whether or not to hospitalize such children. Experience from the United Kingdom
References (112)
- et al.
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology
Blood
(1996) - et al.
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura
Am J Med
(1999) - et al.
Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation
Blood
(1999) - et al.
Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences
Mayo Clin Proc
(1984) - et al.
Idiopathic thrombocytopenic purpura diagnosed during the second decade of life
J Pediatr
(2002) Inherited thrombocytopenia: when a low platelet count does not mean ITP
Blood
(2004)- et al.
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study
Lancet
(2001) - et al.
A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group
J Pediatr
(2003) - et al.
Assessment of UK practice for management of acute childhood idiopathic thrombocytopenia purpura against published guidelines
Lancet
(1997) - et al.
Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children. A prospective Nordic study of an unselected cohort
J Pediatr
(2003)
Idiopathic thrombocytopenic purpura in childhood
J Pediatr
Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome
J Pediatr
The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment
J Pediatr
Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials
J Pediatr
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
Lancet
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura
J Pediatr
Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura
Lancet
Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood
Lancet
Effect of intravenous immunoglobulin in immune thrombocytopenia. Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?
Lancet
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients
Blood
Single dose of anti-D immune globulin at 75 μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children
J Pediatr
Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura
Blood
Arch Pediatr
Hematologic complications of primary immune deficiencies
Blood Rev
Inflammatory and autoimmune complications of common variable immune deficiency
Autoimmun Rev
Common variable immune deficiency and autoimmunity
Autoimmun Rev
Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID)
J Autoimmun
Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome
Clin Immunol
Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)
Blood
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura
Blood
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Blood
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
Exp Hematol
New thrombopoietic growth factors
Blood
Immune thrombocytopenic purpura
N Engl J Med
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura
J Lab Clin Med
Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies
Ann N Y Acad Sci
International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies
Br J Haematol
Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias
Ann Hematol
Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany
Semin Thromb Hemost
Effect of live measles vaccine on the platelet count
N Engl J Med
Idiopathic thrombocytopaenic purpura and MMR vaccine
Arch Dis Child
MMR vaccine and idiopathic thrombocytopenic purpura
Br J Clin Pharmacol
Idiopathic thrombocytopenic purpura in childhood
Can Med Assoc J
Childhood acute immune thrombocytopenic purpura: 20 years later
Semin Thromb Hemost
A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children
Br J Haematol
Childhood ITP: 12 months follow-up data from the prospective Registry I of the Intercontinental Childhood ITP Study Group (ICIS)
Pediatr Blood Cancer
Chronic idiopathic thrombocytopenic purpura: incidence, treatment and outcome
Arch Dis Child
Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity
Eur J Pediatr
on behalf of the Paediatric Haematology Forum of the British Society of Haematology. Intracranial haemorrhage in idiopathic thrombocytopenic purpura
Arch Dis Child
Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis
Neurology
Cited by (59)
Autoimmune- And complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination
2021, Blood AdvancesCitation Excerpt :All are associated with autoimmune disorders and malignancies.13,14 ITP and acquired hemophilia A can be triggered by vaccines10,15-18 and viral infections, including SARS-CoV-2.19,20 The pathogenesis of postviral de novo ITP is thought to involve molecular mimicry and circulating immune complexes.21
Immune thrombocytopenic purpura
2018, Visual Journal of Emergency MedicineCerebral infarctions after intravenous immunoglobulin therapy for ITP in a child
2014, Pediatric NeurologyCitation Excerpt :The goal of therapy is to rapidly increase platelet count, thereby reducing the small but significant risk of intracranial hemorrhage. In patients with intracranial hemorrhage, multiple therapeutic interventions may be used in preparation for emergency splenectomy.1 The benefit–risk ratio of IVIG in ITP is favorable, but rare serious side effects such as thrombosis can occur.
Alternative therapy for persistent childhood immune thrombocytopenic purpura unresponsive to intravenous immunoglobulin
2013, Complementary Therapies in MedicineAcute (Childhood) Immune Thrombocytopenia
2013, Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: Second Edition